Literature DB >> 22057796

[Analysis of muscle function with kinetic superficial EMG in children with haemophilia - recognizing subclinical changes, establishing individual therapy, quality control].

A Seuser1, M Wendel, M Navarrete-Duran, D Fink, G Auerswald, P Böhm.   

Abstract

UNLABELLED: Electromyography (EMG) measures muscle electricity. It depends on muscle contraction and central motor control. Muscles react very sensitive on external signals (e. g. bleeding), The resulting changes can be shown in EMG. PATIENTS,
METHODS: A first study included 51 children and young adults from Costa Rica. They underwent a clinical examination and EMG of the hip, knee and ankle joints. Resting muscle tone, maximal isometric contraction and three typical isotonic movements of the joints were measured. First step of analysis was to characterize typical pathogenic changes in the muscles and to find a corresponding physical therapy to minimize these changes.
RESULTS: It showed that EMG is a good marker for muscle condition. It helps to individualize therapy and improve effectivity of physical and physiotherapeutic treatment of the locomotive system of children and young adults with hemophilia. It can help to recognize early subclinical changes and to control the outcome of therapeutic modalities.

Entities:  

Mesh:

Year:  2011        PMID: 22057796

Source DB:  PubMed          Journal:  Hamostaseologie        ISSN: 0720-9355            Impact factor:   1.778


  2 in total

1.  Evaluation of early musculoskeletal disease in patients with haemophilia: results from an expert consensus.

Authors:  Axel Seuser; Claudia Djambas Khayat; Claude Negrier; Adly Sabbour; Lily Heijnen
Journal:  Blood Coagul Fibrinolysis       Date:  2018-09       Impact factor: 1.276

2.  Establishing an online physical exercise program for people with hemophilia.

Authors:  Barbara Wagner; Axel Seuser; Steffen Krüger; Marie Luca Herzig; Thomas Hilberg; Cihan Ay; Timothy Hasenöhrl; Richard Crevenna
Journal:  Wien Klin Wochenschr       Date:  2019-09-18       Impact factor: 1.704

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.